https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%AE%BE%E7%BE%8E%E6%9B%BF%E5%B0%BC
宾美替尼 - 版本历史
2026-04-18T16:33:08Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E5%AE%BE%E7%BE%8E%E6%9B%BF%E5%B0%BC&diff=317405&oldid=prev
223.160.139.65：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-03-13T06:54:44Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[宾美替尼]]</strong>（<strong>[[Binimetinib]]</strong>，商品名：<strong>[[Mektovi]]</strong>）是一种强效、高选择性的口服小分子<strong>[[MEK1]]</strong>及<strong>[[MEK2]]</strong>（丝裂原活化蛋白激酶激酶）变构抑制剂。作为<strong>[[MAPK]]</strong>（RAS-RAF-MEK-ERK）信号通路的关键调节剂，[[宾美替尼]]通过非竞争性结合[[MEK]]蛋白的变构位点，阻断下游[[ERK]]信号的激活。临床上，该药物通常与[[BRAF抑制剂]]（如[[恩考芬尼]]）联合使用，旨在通过“垂直双重阻断”策略克服单药治疗易产生的代药性。[[宾美替尼]]已获批用于治疗携带<strong>[[BRAF V600]]</strong>突变的不可切除或转移性<strong>[[黑色素瘤]]</strong>及<strong>[[非小细胞肺癌]]</strong>（[[NSCLC]]），是精准肿瘤学领域级联信号阻断的重要支柱。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[宾美替尼]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[Binimetinib]] / [[Mektovi]] · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[Binimetinib]]变构结合模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[MEK1]] / [[MEK2]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">5604([[MAP2K1]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">6840</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Q02750</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[变构MEK抑制剂]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">441.2 Da</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">主要适应症</th><br />
<td style="padding: 12px; color: #0f172a;">[[BRAF突变黑色素瘤]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：阻断MAPK级联反应的关键哨卡</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[宾美替尼]]通过精确干预细胞增殖的核心通路，实现对肿瘤生长的深度抑制：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>变构抑制效应：</strong>[[宾美替尼]]不与[[ATP]]竞争，而是结合在[[MEK]]激酶独特的变构口袋。这种结合方式诱导蛋白构象改变，从而抑制[[RAF]]介导的[[MEK]]激活以及[[MEK]]对下游[[ERK]]的磷酸化。</li><br />
<li style="margin-bottom: 12px;"><strong>协同垂直阻滞：</strong>在携带[[BRAF]]突变的肿瘤中，单一阻断[[RAF]]易诱发反馈性信号代偿。[[宾美替尼]]与[[恩考芬尼]]联合，可从上下游同时封锁通路，显著降低逃逸风险。</li><br />
<li style="margin-bottom: 12px;"><strong>诱导细胞凋亡：</strong>通过持久抑制[[ERK1/2]]的核易位，药物能够下调[[Cyclin D1]]等促增殖蛋白，诱导肿瘤细胞发生G1期阻滞并最终走向凋亡。</li><br />
<li style="margin-bottom: 12px;"><strong>高选择性特征：</strong>对[[MEK1/2]]具有极高的亲和力，对级联以外的其他激酶影响极小，从而优化了治疗窗口。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价矩阵：COLUMBUS研究与前沿进展</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">研究项目/人群</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">方案/分子状态</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床疗效信号([[ORR]]/[[PFS]])</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[COLUMBUS研究]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[宾美替尼]]+[[恩考芬尼]] (BRAF V600)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">中位无进展生存期([[PFS]])达到 14.9个月，显著优于单药对照组。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[PHAROS研究]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[BRAF V600E]] [[NSCLC]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">初治患者客观缓解率([[ORR]])达 75%，展现强劲的一线治疗潜力。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[安全性评估]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">毒性监测</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">常见副反应包括[[浆液性视网膜病变]]、[[肌酸磷酸激酶升高]]及胃肠道反应。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：精准识别与联合用药规范</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[宾美替尼]]的应用需结合严密的分子诊断与全周期的不良反应管理：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>分子准入检查：</strong>用药前必须通过[[NGS]]或[[PCR]]检测确认为[[BRAF V600E]]或[[V600K]]突变阳性。该药不适用于[[BRAF]]野生型患者。</li><br />
<li style="margin-bottom: 12px;"><strong>心脏与眼科监测：</strong>由于[[MEK抑制剂]]的类效应，需定期评估[[左心室射血分数]]([[LVEF]])及进行眼底检查，预防罕见的[[视网膜静脉阻塞]]风险。</li><br />
<li style="margin-bottom: 12px;"><strong>毒性分级干预：</strong>若出现严重的[[CPK(肌酸磷酸激酶)]]升高或[[间质性肺病]]([[ILD]])，应立即暂停给药并进行剂量调整或永久停药。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[恩考芬尼]] (Encorafenib)：</strong>高效[[BRAF抑制剂]]，常与[[宾美替尼]]联用以发挥协同作用。</li><br />
<li style="margin-bottom: 8px;"><strong>[[MAPK级联通路]]：</strong>涉及[[RAS]]-RAF-MEK-ERK的复杂信号网路，是肿瘤增殖的“主控开关”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[曲美替尼]] (Trametinib)：</strong>同类首个获批的[[MEK抑制剂]]，与宾美替尼共同构建了MEK抑制药物矩阵。</li><br />
<li style="margin-bottom: 8px;"><strong>[[BRAF V600E]]：</strong>黑色素瘤中最常见的驱动突变，是[[宾美替尼]]联合方案的核心打击靶标。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Dummer R, et al. (2018).</strong> <em>Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma (COLUMBUS): a multicentre, phase 3 trial.</em> <strong>[[The Lancet Oncology]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：COLUMBUS研究确立了双靶治疗方案在BRAF突变黑色素瘤中的优越疗效，显著延长了患者的生存期。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Riely GJ, et al. (2023).</strong> <em>Phase II PHAROS Study of Encorafenib Plus Binimetinib in BRAF V600E-Mutant Metastatic NSCLC.</em> <strong>[[Journal of Clinical Oncology]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：PHAROS研究证实了宾美替尼联合方案在肺癌领域的精准应用，扩展了其适应症版图。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[宾美替尼]] (Binimetinib) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[MEK1]]•[[MEK2]]•[[BRAF]]•[[ERK]]•[[Cyclin D1]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞品/类似</td><br />
<td style="padding: 10px 15px; color: #334155;">[[曲美替尼]]•[[考比替尼]]•[[司美替尼]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Array BioPharma]]•[[辉瑞]]•[[FDA]]•[[NCCN]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[结直肠癌三联疗法]]•[[攻克NRAS突变耐药]]•[[针对低级别浆液性卵巢癌的探索]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.139.65